MMP2 and urinary bladder cancer: In conclusion, the present study demonstrates that proTAME and its combination therapies with cisplatin and gemcitabine are associated with reduced cell migration and downregulated MMP2 expression in bladder cancer cells, although further studies are necessary to determine whether these effects reflect anti-migratory activity or indirect influences on cell viability and stress responses.